See more : Zhongfu Information Inc. (300659.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Giant Biogene Holding Co., Ltd. (2367.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Giant Biogene Holding Co., Ltd., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
- Ultimate Sports Entertainment, Inc. (ULSP) Income Statement Analysis – Financial Results
- Jaya Tiasa Holdings Berhad (4383.KL) Income Statement Analysis – Financial Results
- Raymond Lifestyle Limited (RAYMONDLSL.BO) Income Statement Analysis – Financial Results
- Milestone Pharmaceuticals Inc. (MIST) Income Statement Analysis – Financial Results
- Forma Therapeutics Holdings, Inc. (FMTX) Income Statement Analysis – Financial Results
Giant Biogene Holding Co., Ltd. (2367.HK)
About Giant Biogene Holding Co., Ltd.
Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It also manufactures rare ginsenosides technology-based functional foods; and offers medical devices. The company offers its functional skincare products, medical dressings, and functional foods primarily under the Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 3.52B | 2.36B | 1.55B | 1.19B | 956.70M |
| Cost of Revenue | 577.01M | 369.21M | 198.15M | 183.41M | 159.99M |
| Gross Profit | 2.95B | 2.00B | 1.35B | 1.01B | 796.71M |
| Gross Profit Ratio | 83.63% | 84.39% | 87.24% | 84.59% | 83.28% |
| Research & Development | 74.97M | 44.04M | 24.95M | 13.38M | 11.40M |
| General & Administrative | 96.66M | 111.07M | 20.25M | 9.05M | 7.57M |
| Selling & Marketing | 1.16B | 706.37M | 332.89M | 153.26M | 90.52M |
| SG&A | 1.26B | 817.44M | 353.14M | 162.31M | 98.09M |
| Other Expenses | 0.00 | -44.17M | 47.53M | 22.31M | 9.55M |
| Operating Expenses | 1.28B | 817.32M | 425.62M | 198.00M | 119.05M |
| Cost & Expenses | 1.83B | 1.19B | 623.77M | 381.41M | 279.04M |
| Interest Income | 47.49M | 13.16M | 9.41M | 9.88M | 16.18M |
| Interest Expense | 112.00K | 21.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 34.18M | 27.63M | 24.21M | 22.29M | 17.88M |
| EBITDA | 1.78B | 1.21B | 938.78M | 674.10M | 706.53M |
| EBITDA Ratio | 50.49% | 51.36% | 60.47% | 56.62% | 73.85% |
| Operating Income | 1.66B | 1.19B | 914.57M | 651.81M | 688.64M |
| Operating Income Ratio | 47.24% | 50.19% | 58.91% | 54.75% | 71.98% |
| Total Other Income/Expenses | 80.22M | -876.00K | 41.25M | 168.49M | -668.00K |
| Income Before Tax | 1.75B | 1.18B | 972.92M | 973.24M | 677.00M |
| Income Before Tax Ratio | 49.52% | 49.81% | 62.67% | 81.75% | 70.76% |
| Income Tax Expense | 296.89M | 176.16M | 144.79M | 146.76M | 101.82M |
| Net Income | 1.45B | 1.00B | 828.13M | 826.45M | 552.26M |
| Net Income Ratio | 41.19% | 42.38% | 53.34% | 69.42% | 57.73% |
| EPS | 1.48 | 0.99 | 0.84 | 0.83 | 0.56 |
| EPS Diluted | 1.48 | 0.98 | 0.84 | 0.83 | 0.56 |
| Weighted Avg Shares Out | 980.91M | 976.00M | 974.79M | 991.61M | 991.61M |
| Weighted Avg Shares Out (Dil) | 982.72M | 1.02B | 991.61M | 991.61M | 991.61M |
Source: https://incomestatements.info
Category: Stock Reports